相关实验视频
Updated: Sep 10, 2025

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.6K
一系列与vildagliptin相关的乳头 - - 罕见的副作用
Mohit Kumar Shahi1, J V Ashwin1, Astha Singh2
1Department of GMH, King George Medical University, Lucknow, Uttar Pradesh, India.
Indian journal of pharmacology
|August 22, 2025
概括
一种常见的口服低血糖剂Vildagliptin可能会引发囊性皮肤病. 这一系列病例强调了三名患者在开始治疗2型糖尿病时出现了这种自身免疫性疾病.
科学领域:
- 内分泌学
- 皮肤病学
- 免疫学
背景情况:
- 维尔达格利普丁是一种口服低血糖剂 (OHA),属于双酶-4 (DPP-4) 抑制剂类.
- DPP-4 抑制剂广泛用于治疗2型糖尿病 (T2DM).
- 囊炎 (BP) 是一种自身免疫性水泡性疾病,影响皮肤和粘膜.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416

